SEIZE THE $50 BILLION SITE-OF-CARE SHIFT OPPORTUNITY
Get the tools, data, and insights to drive growth.
Learn more

 We are pausing publication of The Daily Briefing out of respect for the tragic passing of Brian Thompson. We will resume publication of this daily newsletter in the coming days.

Daily Briefing

Around the nation: 23andMe data breach affects nearly 7M people


23andMe on Monday announced that a data breach allowed hackers to access the personal information of around 6.9 million people, in today's bite-sized hospital and health industry news from California, Florida, and Indiana.

  • California: 23andMe on Monday announced that a data breach allowed hackers to access the personal information of around 6.9 million people. In some cases, this included people's ancestry trees, birth years, and geographic locations. The hackers used old passwords that 23andMe customers had used on other sites and were initially able to breach around 14,000 profiles, according to a disclosure with the Securities and Exchange Commission. That breach then opened the door to millions of other customer profiles. A spokesperson for 23andMe noted the company has "not learned of any reports of inappropriate use of the data after the leak." (Carballo, New York Times, 12/4)
  • Florida: Panera Bread is being sued for the death of Dennis Brown, a resident of Fleming Island, Florida, who consumed three of the restaurant's Charged Lemonades on Oct. 9 and suffered a fatal cardiac arrest on his way home. The lawsuit comes two months after a separate lawsuit was filed against Panera for the death of Sarah Katz, a 21-year-old student with a heart condition who died in September 2022 after consuming a Charged Lemonade. The Charged Lemonade drink contains 390 milligrams of caffeine — more than any size of Panera's dark roast coffee, the lawsuits say, and more than the caffeine content of standard Red Bull and Monster energy drinks combined. According to FDA, healthy adults can safely consume 400 milligrams of caffeine a day. (Chuck, NBC News, 12/4)
  • Indiana: Roche on Monday announced it is acquiring Carmot Therapeutics for $2.7 billion, with additional milestone payments of up to $400 million. As part of the deal, Roche will acquire three experimental obesity drugs from Carmot that are in Phase 1 or Phase 2 testing. All the drugs target GLP-1 hormone receptors, and two are designed to work through receptors for a different hormone called GIP. In a statement, Roche said the drug candidates owned by Carmot complemented medicines Roche had in its own pipeline, including some that are focused on preserving muscle mass. (Joseph, STAT+ [subscription required], 12/4)

Data privacy and the FTC: Who is working to protect your data?

While the healthcare industry wrestles with some concerns about data privacy, the question remains: who is working to protect the data of consumers and patients?

Radio Advisory's Rachel Woods sat down with Advisory Board experts Ty Aderhold, Sara Zargham, and Paul Trigonoplos to discuss one stakeholder that is making moves to protect data privacy: the Federal Trade Commission (FTC). In the conversation, they explore recent regulatory actions taken by the FTC and what this means for the industry. Read a lightly edited excerpt from the conversation and download the episode below.


SPONSORED BY

INTENDED AUDIENCE

AFTER YOU READ THIS

AUTHORS

TOPICS

INDUSTRY SECTORS

RELATED RESOURCES

Don't miss out on the latest Advisory Board insights

Create your free account to access 1 resource, including the latest research and webinars.

Want access without creating an account?

   

You have 1 free members-only resource remaining this month.

1 free members-only resources remaining

1 free members-only resources remaining

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox

You've reached your limit of free insights

Become a member to access all of Advisory Board's resources, events, and experts

Never miss out on the latest innovative health care content tailored to you.

Benefits include:

Unlimited access to research and resources
Member-only access to events and trainings
Expert-led consultation and facilitation
The latest content delivered to your inbox
AB
Thank you! Your updates have been made successfully.
Oh no! There was a problem with your request.
Error in form submission. Please try again.